Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rentschler Expands Single-Use Manufacturing Capacities

Published: Saturday, June 07, 2014
Last Updated: Saturday, June 07, 2014
Bookmark and Share
Company announces addition of a 2,000 L single-use bioreactor to its facility.

Rentschler Biotechnologie GmbH has announced the addition of a 2,000 L single-use bioreactor to its facility in Laupheim. The expansion is anticipated to be fully operational end of the first quarter of 2015.

The new 2,000 L single-use bioreactor will supplement two existing 1,000 L single-use bioreactors already in operation and will double the total single-use production capacity.

“We see an increasing need for production capacity in the mid-scale. The expansion will allow us to match the growing demands of our clients for all clinical phases. The addition of the 2,000 L single-use bioreactor will increase our flexibility to serve the market with either stainless steel or single-use technology as the client requires”, explains Frank Ternes, Chief Business Officer at Rentschler.

In 2012, Rentschler has received the “Facility of the Year Award” for its flexible, multi-product 1,000 L manufacturing facility designed to minimize manufacturing costs and product cycle times. Single-use equipment reduces contamination risks and permits a faster product turnaround with a shortened setup time and hence increases the capacity utilization.

The facility features a flexible space concept comprising four independent, connectable, multi-purpose clean room suites. The new 2,000 L single-use bioreactor seamlessly integrates in this proven facility concept.

Rentschler is one of the first CMOs having established a fully disposable process concept and already has more than three years of experience with this system.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rentschler Invests EUR 24 Million in Stainless Steel Bioreactor Manufacturing
The Twin system should be operational in early 2017.
Saturday, June 21, 2014
New Campaign for Rentschler's 'Facility of the Year'
Company has launched a new website to coincide with BIO 2012.
Tuesday, July 17, 2012
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!